JP7354106B2 - レプリコン粒子および油性アジュバントによるワクチン接種 - Google Patents

レプリコン粒子および油性アジュバントによるワクチン接種 Download PDF

Info

Publication number
JP7354106B2
JP7354106B2 JP2020530342A JP2020530342A JP7354106B2 JP 7354106 B2 JP7354106 B2 JP 7354106B2 JP 2020530342 A JP2020530342 A JP 2020530342A JP 2020530342 A JP2020530342 A JP 2020530342A JP 7354106 B2 JP7354106 B2 JP 7354106B2
Authority
JP
Japan
Prior art keywords
oil
vaccine
animal
based adjuvant
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505558A (ja
Inventor
モグラー，マーク・エー
ストレート，エリン
セヘルス，ルード・フィリップ・アントン・マリア
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2021505558A publication Critical patent/JP2021505558A/ja
Priority to JP2023121307A priority Critical patent/JP7696960B2/ja
Application granted granted Critical
Publication of JP7354106B2 publication Critical patent/JP7354106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020530342A 2017-12-04 2018-12-03 レプリコン粒子および油性アジュバントによるワクチン接種 Active JP7354106B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023121307A JP7696960B2 (ja) 2017-12-04 2023-07-26 レプリコン粒子および油性アジュバントによるワクチン接種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594342P 2017-12-04 2017-12-04
US62/594,342 2017-12-04
US201762607101P 2017-12-18 2017-12-18
US62/607,101 2017-12-18
PCT/EP2018/083297 WO2019110481A1 (en) 2017-12-04 2018-12-03 Vaccination with replicon particles and oil adjuvant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121307A Division JP7696960B2 (ja) 2017-12-04 2023-07-26 レプリコン粒子および油性アジュバントによるワクチン接種

Publications (2)

Publication Number Publication Date
JP2021505558A JP2021505558A (ja) 2021-02-18
JP7354106B2 true JP7354106B2 (ja) 2023-10-02

Family

ID=64661329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020530342A Active JP7354106B2 (ja) 2017-12-04 2018-12-03 レプリコン粒子および油性アジュバントによるワクチン接種
JP2023121307A Active JP7696960B2 (ja) 2017-12-04 2023-07-26 レプリコン粒子および油性アジュバントによるワクチン接種

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023121307A Active JP7696960B2 (ja) 2017-12-04 2023-07-26 レプリコン粒子および油性アジュバントによるワクチン接種

Country Status (9)

Country Link
US (2) US12239702B2 (https=)
EP (1) EP3720488A1 (https=)
JP (2) JP7354106B2 (https=)
KR (2) KR20250116783A (https=)
CN (2) CN120771270A (https=)
BR (1) BR112020011044A2 (https=)
CA (1) CA3084042A1 (https=)
MX (2) MX2020005584A (https=)
WO (1) WO2019110481A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720489A1 (en) * 2017-12-04 2020-10-14 Intervet International B.V. Canine lyme disease vaccine
EP4168429A1 (en) * 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
BR112022025678A2 (pt) * 2020-06-19 2023-01-17 Intervet Int Bv Vacina contra o vírus da influenza a suína compreendendo duas partículas de replicon de rna distintas
BR112023004123A2 (pt) 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
AR124849A1 (es) 2021-02-11 2023-05-10 Intervet Int Bv Vacuna para mycoplasma bovis
MX2024000544A (es) 2021-07-13 2024-04-09 Intervet Int Bv Superacion de la interferencia de los anticuerpos en las aves.
US20250281597A1 (en) 2021-10-25 2025-09-11 Intervet Inc. A vaccine for the protection of piglets against swine influenza a virus infection

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516333A (ja) 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
WO2005007689A1 (en) 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
JP2013531680A (ja) 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
WO2013131565A1 (en) 2012-03-07 2013-09-12 Ceva Sante Animale Novel veterinary vaccine
JP2014522840A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
WO2017162741A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
JPH11269093A (ja) 1998-01-22 1999-10-05 Shionogi & Co Ltd 油性アジュバントワクチン製剤
KR20060017635A (ko) 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
CN1989250B (zh) 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
US7805252B2 (en) 2005-08-16 2010-09-28 Dna Twopointo, Inc. Systems and methods for designing and ordering polynucleotides
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
US8425922B2 (en) * 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
RU2580299C2 (ru) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Вакцины и композиции, направленные против streptococcus pneumoniae
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
HUE028877T2 (en) 2010-08-27 2017-01-30 Intervet Int Bv Test of biological activity of vaccine formulation
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
PL2714908T3 (pl) 2011-05-26 2018-07-31 Intervet International B.V. Oligodeoksynukleotydy immunostymulacyjne
MX346596B (es) 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US20150140068A1 (en) * 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
EP3076997B1 (en) * 2013-12-03 2018-08-29 Intervet International B.V. Swine vaccine against prrs and lawsonia intracellularis
EP3191125B1 (en) 2014-09-12 2024-11-20 Intervet International B.V. Vaccine for use in protecting offspring of a sow against porcine endemic diarrhea virus
EP3558351B1 (en) 2016-12-23 2022-01-26 Intervet International B.V. Combination vaccine for swine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516333A (ja) 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
WO2005007689A1 (en) 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
JP2013531680A (ja) 2010-07-06 2013-08-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2014522840A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
WO2013131565A1 (en) 2012-03-07 2013-09-12 Ceva Sante Animale Novel veterinary vaccine
WO2017162741A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Poultry Science, 1995, Vol.74, No.4, pp.666-671

Also Published As

Publication number Publication date
WO2019110481A1 (en) 2019-06-13
KR20200095479A (ko) 2020-08-10
CA3084042A1 (en) 2019-06-13
CN111447948A (zh) 2020-07-24
JP7696960B2 (ja) 2025-06-23
MX2023012390A (es) 2023-11-01
MX2020005584A (es) 2020-09-14
KR102854574B1 (ko) 2025-09-03
US20250319175A1 (en) 2025-10-16
JP2021505558A (ja) 2021-02-18
BR112020011044A2 (pt) 2020-11-17
US20200323975A1 (en) 2020-10-15
RU2020119613A3 (https=) 2022-04-14
CN120771270A (zh) 2025-10-14
RU2020119613A (ru) 2022-01-12
KR20250116783A (ko) 2025-08-01
EP3720488A1 (en) 2020-10-14
US12239702B2 (en) 2025-03-04
CN111447948B (zh) 2025-09-02
JP2023145596A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7354106B2 (ja) レプリコン粒子および油性アジュバントによるワクチン接種
CA2725435C (en) Vaccines for inclusion body hepatitis
Lin et al. Novel subunit vaccine with linear array epitope protect giant grouper against nervous necrosis virus infection
JP7346417B2 (ja) ブタインフルエンザａウイルスワクチン
JP2022538673A (ja) アフリカ豚熱ワクチン
CN115697398A (zh) 包含两种不同rna复制子颗粒的甲型猪流感病毒疫苗
US20250281597A1 (en) A vaccine for the protection of piglets against swine influenza a virus infection
RU2806690C2 (ru) Вакцинация частицами репликона и масляным адъювантом
Elizaveta et al. Live poultry vaccines against highly pathogenic avian influenza viruses
JP7513614B2 (ja) プライム－ブーストワクチン接種レジメン
BR122025027501A2 (pt) Vacina com partículas de replicon e adjuvante de óleo, kit, uso e partícula de replicon de rna de alfavírus de encefalite equina venezuelana (vee) que codifica um antígeno originário de um patógeno de animal
CN115768785A (zh) 包含含有编码病毒的不同神经氨酸酶抗原的第一、第二和第三核酸序列的核酸构建体的甲型猪流感病毒疫苗
RU2323741C2 (ru) Вакцина против гриппа птиц инактивированная эмульсионная
Hoppes et al. Vaccination Strategies
RU2787596C9 (ru) Вакцина к вирусу свиного гриппа a
RU2787596C2 (ru) Вакцина к вирусу свиного гриппа a
CN116528893A (zh) 用于ha抗体阳性靶标的ha茎疫苗
RU2213576C1 (ru) Способ изготовления инактивированной эмульсионной вакцины против синдрома гидроперикардита кур
CN115836082A (zh) 包含编码特定病毒谱系抗原的核酸构建体的甲型猪流感病毒疫苗
Hsieh Approaches to enhance protection against infectious bursal disease in chickens conferred by DNA-mediated vaccination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230920

R150 Certificate of patent or registration of utility model

Ref document number: 7354106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150